Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

56.96
Delayed Data
As of Feb 11
 -0.04 / -0.07%
Today’s Change
53.26
Today|||52-Week Range
140.00
-39.49%
Year-to-Date

Today’s Trading

Previous close57.00
Today’s open55.60
Day’s range53.26 - 58.33
Volume1,402,045
Average volume (3 months)963,553
Market cap$4.8B
Dividend yield--
Data as of 4:00pm ET, 02/11/2016

Growth & Valuation

Earnings growth (last year)-234.48%
Earnings growth (this year)+31.23%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+7.20%
P/E ratioNM
Price/Sales142.50
Price/Book4.70

Competitors

 Today’s
change
Today’s
% change
IONSIonis Pharmaceutical...+1.22+3.69%
ICLRICON PLC-0.61-0.92%
CRLCharles River Labora...-1.20-1.67%
PRXLPAREXEL Internationa...-0.13-0.22%
Data as of 4:02pm ET, 02/11/2016

Financials

Last reporting dateFebruary 12, 2016
EPS forecast (this quarter)-$0.94
Annual revenue (last year)$50.6M
Annual profit (last year)-$360.4M
Net profit margin-712.79%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers